Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E22.30 EPS (ttm)3.62 Insider Own0.10% Shs Outstand1.48B Perf Week2.64%
Market Cap119.69B Forward P/E8.57 EPS next Y9.43 Insider Trans-15.86% Shs Float1.47B Perf Month-0.04%
Income5.74B PEG2.33 EPS next Q2.05 Inst Own72.30% Short Float1.48% Perf Quarter-5.60%
Sales32.75B P/S3.65 EPS this Y4.80% Inst Trans-1.59% Short Ratio3.02 Perf Half Y-15.53%
Book/sh-5.70 P/B- EPS next Y8.63% ROA8.80% Target Price92.18 Perf Year-28.92%
Cash/sh5.44 P/C14.85 EPS next 5Y9.58% ROE-202.20% 52W Range75.77 - 114.15 Perf YTD-12.33%
Dividend4.28 P/FCF16.60 EPS past 5Y7.60% ROI21.80% 52W High-29.31% Beta1.15
Dividend %5.30% Quick Ratio0.90 Sales past 5Y11.80% Gross Margin76.90% 52W Low6.49% ATR1.46
Employees30000 Current Ratio1.00 Sales Q/Q7.30% Oper. Margin19.50% RSI (14)48.62 Volatility2.21% 1.80%
OptionableYes Debt/Eq- EPS Q/Q-516.50% Profit Margin17.30% Rel Volume0.46 Prev Close80.82
ShortableYes LT Debt/Eq- EarningsApr 26 BMO Payout100.30% Avg Volume7.25M Price80.69
Recom2.70 SMA201.55% SMA50-1.20% SMA200-9.84% Volume823,837 Change-0.16%
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-19-19 10:21AM  Why You Should Buy ABBV Stock for Income and Value InvestorPlace
09:36AM  FDA puts partial hold on clinical trials of AbbVie's cancer drug Reuters
09:07AM  AbbVie stock down 0.8% after FDA places hold on clinical trials of venetoclax as a treatment for multiple myeloma MarketWatch
09:01AM  FDA puts partial hold on clinical trials of AbbVie's cancer drug Reuters
08:45AM  AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program PR Newswire
Mar-18-19 05:45PM  AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know Zacks
01:36PM  Big Pharma Earnings Might Not Be as Good as They Look
Mar-17-19 09:03AM  2 Things Investors Are Missing About AbbVie Motley Fool
Mar-14-19 10:36AM  Roche Receives EC Approval for Label Expansion of Hemlibra Zacks
09:14AM  3 Dividend Aristocrats to Buy and Hold Forever Motley Fool
06:00AM  The Timely Ten- Blue Chip Buys with Value and Yield MoneyShow
05:01AM  Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades Investopedia
Mar-13-19 02:27PM  Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study Zacks
08:37AM  FDA medical adviser: 'Congress is owned by pharma' Yahoo Finance
Mar-12-19 05:07PM  Takeda's Entyvio Tops AbbVie's Humira in Patients With Ulcerative Colitis
10:50AM  Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval Zacks
Mar-11-19 05:45PM  AbbVie (ABBV) Gains But Lags Market: What You Should Know Zacks
11:05AM  Should Value Investors Consider Abbvie (ABBV) Stock Now? Zacks
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
09:00AM  4 Stocks to Buy With Dividends Yielding More Than 4% Motley Fool
Mar-08-19 01:45PM  Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs Zacks
10:20AM  Dont Abandon Gilead Stock After Weak Q4 Results InvestorPlace
09:35AM  Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC Zacks
Mar-07-19 03:32PM  The Kiplinger Dividend 15 Is On a Roll Kiplinger
10:35AM  UPDATE: Bio-Path stock gains another 130% on Thursday MarketWatch
08:46AM  AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment in Previously-Untreated Chronic Lymphocytic Leukemia Patients PR Newswire
08:40AM  Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed Zacks
06:03AM  2 Biotech Stocks With Major Incoming Catalysts Motley Fool
Mar-06-19 01:32PM  7 Stocks That Can Outperform In a Post QE Market Investopedia
09:15AM  Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice Zacks
Mar-05-19 03:05PM  Top Marijuana Stocks That Pay Dividends Investopedia
09:51AM  The Zacks Analyst Blog Highlights: Intel, AbbVie, United Technologies, Simon Property and FirstEnergy Zacks
Mar-04-19 03:27PM  Top Research Reports for Intel, AbbVie & United Technologies Zacks
10:05AM  AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab Zacks
Mar-01-19 09:29AM  Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices Zacks
08:00AM  AbbVie to Present at the Barclays Global Healthcare Conference PR Newswire
07:00AM  AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI) for the Treatment of Moderate to Severe Plaque Psoriasis PR Newswire
Feb-28-19 02:44PM  These 10 New Drugs Expected In 2019 Are On The Blockbuster Track Investor's Business Daily
02:16PM  Is now the time to buy Rio Tinto? How does Abbvie look here? The desk answers your questions CNBC Videos
11:24AM  3 Top Stocks With High Dividend Yields Motley Fool
08:00AM  AbbVie to Present at the Cowen Health Care Conference PR Newswire
05:00AM  10 Stocks With Safe, Generous Dividends
Feb-27-19 03:49PM  Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You Motley Fool
11:20AM  The patent system keeps American drug prices so high Yahoo Finance Video
06:00AM  Senate panel grills pharma CEO over executive bonuses. Calls tie to sales of AbbVie blockbuster drug Humira 'problematic' CNBC
Feb-26-19 09:22PM  Voyager Therapeutics, Inc. (VYGR) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:35PM  Senators Press Drug-Company Executives Over Prices The Wall Street Journal
06:16PM  Lawmakers grill top pharma execs over high drug costs CNBC Videos
04:30PM  [$$] CEOs From Pfizer, Merck and Others Face Senate Over Drug Pricing The Wall Street Journal
03:40PM  Why Big Pharmas Case to Congress Comes Up Short Bloomberg
03:19PM  Congress Grills Drugmakers: 5 Key Takeaways Motley Fool
03:03PM  There Are Many Reasons to Still Like AbbVie
02:48PM  Drugmakers CEOs clash with senators in hearing on drug price hikes MarketWatch
11:02AM  Senators grills pharma execs for raising drug prices, protecting patents 'like Gollum with his ring' CNBC
10:15AM  Pharma execs offer Senate ideas to lower drug costs except actually cutting prices CNBC
09:45AM  Drugmakers CEOs set to get grilled at Senate hearing on rising drug prices MarketWatch
09:42AM  It Could Be Time For This Pharma ETF Benzinga
07:49AM  Sen. Grassley says probe of 'secretive' drug industry pricing won't stop with drugmakers CNBC
07:00AM  3 Top Dividend Stocks With Yields Over 5% Motley Fool
02:22AM  [$$] US drugmakers defend pricing under fire in Senate Financial Times
Feb-25-19 07:50PM  [$$] Pharmaceutical Industry CEOs Face Senate Hearing on Drug Prices The Wall Street Journal
05:54PM  Technician says it's time to fade the biotech rally CNBC Videos
05:08PM  Factbox: Pharma company executives to testify at U.S. Senate drug price hearing Reuters
03:15PM  [$$] Pharmaceutical Industry CEOs Face Senate Hearing on Drug Prices The Wall Street Journal
10:28AM  Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat Zacks
09:59AM  The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie Zacks
08:31AM  AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting PR Newswire
08:19AM  AbbVie Extends Deal With Voyager to Make Parkinson's Drugs Zacks
Feb-24-19 09:30AM  Why Is AbbVie (ABBV) Down 6.8% Since Last Earnings Report? Zacks
Feb-22-19 12:25PM  Why Voyager Therapeutics Is Skyrocketing Today Motley Fool
11:31AM  Voyager Therapeutics stock jumps on 2nd Parkinson's deal American City Business Journals
09:46AM  Voyager Shares Take Off on Parkinson's Disease Development Deal
09:04AM  Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates Zacks
08:10AM  Voyager Therapeutics stock soars after AbbVie collaboration potentially valued at over $1 billion MarketWatch
08:00AM  AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies PR Newswire
Feb-21-19 09:39PM  What Pharma Investors Need to Know About Pfizer's Latest Disaster Motley Fool
01:21PM  AbbVie Declares Quarterly Dividend PR Newswire
07:32AM  The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan Benzinga
06:59AM  Waltham biotech Morphic signs $725M partnership with Janssen American City Business Journals
Feb-20-19 12:18PM  AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review Zacks
Feb-19-19 07:26PM  U.S. settles with Teva over keeping generic drugs off market Reuters
04:41PM  Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review Zacks
09:29AM  2 Pharma Stocks in the Middle of an Oncology Sales Explosion Motley Fool
08:56AM  AbbVie stock up 0.2% after FDA grants upadacitinib priority review status MarketWatch
08:31AM  AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis PR Newswire
Feb-18-19 05:00AM  Investors Miss the Mark on AbbVie's Strong Pipeline MoneyShow
Feb-16-19 10:04AM  These 3 Value Stocks Are Absurdly Cheap Right Now Motley Fool
Feb-15-19 04:16PM  AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc. Moody's
08:01AM  [$$] WSJ Tax Guide 2019: The Drug Industry The Wall Street Journal
Feb-13-19 09:15AM  AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy? Zacks
Feb-12-19 09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
05:00AM  5 Aristocrats for Stable Income MoneyShow
Feb-11-19 03:24PM  5 High-Growth Stocks Undervalued by the Market InvestorPlace
02:46PM  Here's Why Coherus BioSciences Rose 48.7% in January Motley Fool
08:00AM  AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma PR Newswire
Feb-09-19 09:00AM  Here's Why AbbVie's Stock Tanked in January Motley Fool
Feb-08-19 01:58PM  Does FedEx look good here? What's the deal with McKesson? Buy Abbvie? CNBC Videos
Feb-06-19 08:43PM  Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript Motley Fool
05:52PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
01:33PM  At least four pharma CEOs to testify at Senate drug pricing hearing Reuters
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid for hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers. AbbVie Inc. has collaborations with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Universite de Montreal; Tolero Pharmaceuticals, Inc.; Galapagos; Mission Therapeutics Ltd; Bristol-Myers Squibb Company; Voluntis; Tizona Therapeutics, Inc.; and Voyager Therapeutics, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM